Charts
19 Apr, 2024
18 Apr, 2024
17 Apr, 2024
16 Apr, 2024
15 Apr, 2024
12 Apr, 2024
11:48
Seeking Alpha
11 Apr, 2024
10 Apr, 2024
09 Apr, 2024
News
17 Apr, 2024
12:42
FinancialContent
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist On Hearings
The Drug Enforcement Administration ...
03 Apr, 2024
17:56
FinancialContent
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the ...
Gainers
ARCA biopharma (NASDAQ:ABIO) stock moved upwards by 124.6% to $3.84 during Wednesday's pre-market session. The market value of ...
02 Apr, 2024
Gainers
OneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their ...
01 Apr, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
The post ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023 appeared first on InvestorPlace.
More From InvestorPlace
The #1 AI Investment Might Be This Company You’ve Never Heard Of
Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
It doesn’t matter if you have $500 or $5 million. Do this now.
29 Mar, 2024
16:43
FinancialContent
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
Partners Beckley Psytech and atai Life Sciences ...
27 Mar, 2024
12:59
FinancialContent
Nasdaq-listed psychedelics biotech Enveric Biosciences (NASDAQ:ENVB) shared its financial results for the fourth quarter of 2023 and the ...
26 Mar, 2024
11:00
FinancialContent
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023.
11:00
Yahoo! Finance
CAMBRIDGE, Mass., March 26, 2024--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023.
20 Mar, 2024
18:49
FinancialContent
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & ...
19 Mar, 2024
17:48
FinancialContent
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected ...
U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 100 points on Tuesday.
Following the market opening ...
13:34
FinancialContent
Enveric Biosciences(NASDAQ:ENVB) shares are trading higher after the company signed two non-binding term sheets with an ...
Gainers
Ontrak (NASDAQ:OTRK) shares rose 173.2% to $0.52 during Tuesday's pre-market session. The company's market cap stands at $14.3 ...
11:00
FinancialContent
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that it has signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applications for treatment of joint diseases.
16 Mar, 2024
13:58
FinancialContent
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items concerning the first two weeks of March ...
12 Mar, 2024
11:00
FinancialContent
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that, on March 5, 2024, the United States Patent and Trademark Office issued U.S. Patent No. 11,918,594, titled “Multi-Substituent Psilocybin Derivatives” and is further expected to issue, on March 19, 2024, U.S. Patent No. 11,931,338, titled “Nitrilated Psilocybin Derivatives”.
04 Mar, 2024
18:48
FinancialContent
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety
Psilocybin-assisted therapy has ...
29 Feb, 2024
U.S. stocks traded mixed toward the end of trading, with the S&P 500 gaining around 0.3% on Thursday.
The Dow traded down 0.08% ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Investors in Enveric Biosciences are seeing massive gains today, as ENVB stock more than doubles on a huge uptick in trading volume.
The post Why Is Enveric Biosciences (ENVB) Stock Up 120% Today? appeared first on InvestorPlace.
More From InvestorPlace
ChatGPT IPO Could Shock the World, Make This Move Before the Announcement
Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
It doesn’t matter if you have $500 or $5 million. Do this now.
19:00
FinancialContent
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed ...
Gainers
Societal CDMO (NASDAQ:SCTL) stock rose 132.6% to $1.07 during Thursday's regular session. The company's market cap stands at ...
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday.
The Dow traded down ...
Enveric Biosciences, Inc. (NASDAQ:ENVB) shares are soaring Thursday after the company announced it has signed three non-binding term ...
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday.
Following the market ...
Gainers
Enveric Biosciences (NASDAQ:ENVB) stock rose 162.3% to $2.18 during Thursday's pre-market session. The company's market cap ...
12:27
FinancialContent
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the news affecting shares this morning!
The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace.
More From InvestorPlace
The #1 AI Investment Might Be This Company You’ve Never Heard Of
“America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out
It doesn’t matter if you have $500 or $5 million. Do this now.
12:00
FinancialContent
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that it has signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds. The compounds come from Enveric’s extensive library of over 1,000 novel molecules generated using the Company’s Psybrary™ platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (PsyAI™).
11:34
FinancialContent
Enveric Biosciences (NASDAQ:ENVB), a Florida-headquartered biotech company developing novel neuroplasticity-promoting small molecule ...
26 Feb, 2024
13:00
CORRECTION – Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)
Yahoo! Finance
In a release issued under the same headline on August 24, 2023 by Diamond Equity Research LLC, please note that the Disclosures paragraph has been replaced and includes the correct amount paid upfront for sponsored research, disregard all previous press release Disclosures on this ticker. The corrected release follows: NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note
23 Feb, 2024
18:51
FinancialContent
Enveric Biosciences Inc. (NASDAQ:ENVB) said on Friday it has agreed to sell one of its cancer-related patent portfolios. The Cambridge, ...
Gainers
Maravai LifeSciences (NASDAQ:MRVI) stock increased by 65.5% to $8.46 during Friday's regular session. The company's market cap ...
Gainers
Enveric Biosciences (NASDAQ:ENVB) shares increased by 83.5% to $1.56 during Friday's pre-market session. The company's market ...
13:00
FinancialContent
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company has agreed to sell one of its cancer-related patent portfolios for an undisclosed amount. Enveric plans to continue to focus and invest in the development of its lead candidates EB-003, a first-in-class neuroplastogen designed to eliminate hallucinations, and EB-002, formerly EB-373, a next generation synthetic prodrug of the active metabolite, psilocin.
21 Feb, 2024
13:01
Enveric Biosciences Deepens Its Mental Health-Focused Pipeline With Library of Preclinical Compounds
FinancialContent
Enveric Biosciences(NASDAQ:ENVB) announced the discovery of multiple compounds sourced using its Psybrary platform and proprietary ...
13:00
FinancialContent
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the discovery of multiple, promising novel compounds sourced using the company’s Psybrary™ platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (PsyAI™). The novel compounds span seven distinct molecule classes totaling at least 57 unique product opportunities, all of which are protected by Enveric’s expansive intellectual property portfolio and represent potential out-licensing opportunities and non-dilutive revenue streams for the Company.
15 Feb, 2024
13:36
FinancialContent
Can Psychedelics Increase Sexual Interest And Satisfaction? Study Says Yes And Effects Can Last Months
A new study suggests a ...
27 Jan, 2024
15:00
FinancialContent
New Study Reveals Suggestibility’s Role In Antidepressant Effects Of Psilocybin Therapy
A new study led by Balázs Szigeti and ...
12 Jan, 2024
21:55
FinancialContent
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
A decade after it was founded as a ...
11 Jan, 2024
00:56
FinancialContent
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential ...
07 Jan, 2024
17:36
FinancialContent
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury
Results of a first-in-class clinical trial on ...
03 Jan, 2024
13:00
FinancialContent
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided an update on data underpinning the selection of EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series. As previously announced, EB-003 was selected based on data analyses suggesting the molecule’s potential to be a first-in-class approach to addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations.
01 Jan, 2024
Gainers
China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 185.1% to $5.73 during Monday's pre-market session. The company's ...
29 Dec, 2023
18:03
FinancialContent
Shares of Fisker Inc. (NYSE: FSR) rose sharply during Friday’s session after the company provided a December 2023 business ...
13:52
FinancialContent
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,122,000 shares of the Company’s common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.37 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $1.8 million, before deducting financial advisory fees. The reduction of the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules.
28 Dec, 2023
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has named EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series. EB-003 was selected based on data analyses suggesting the molecule’s potential to be a first-in-class approach to addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Enveric plans to initiate preclinical development of EB-003 in early 2024 in preparation for an Investigational New Drug (IND) application for a first-in-human clinical trial.
27 Dec, 2023
15:09
FinancialContent
President Biden Approves Psychedelics Clinical Trials For Active Military Members
President Bidensigned into law the 2024 ...
13:00
FinancialContent
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the GLP Safety and Toxicology Program of EB-373 is proceeding as planned thus far with favorable results.
20 Dec, 2023
13:00
FinancialContent
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, announced the company will participate in Biotech Showcase 2024 being held January 8-10, 2024 in San Francisco.
13:00
Yahoo! Finance
CAMBRIDGE, Mass., December 20, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, announced the company will participate in Biotech Showcase 2024 being held January 8-10, 2024 in San Francisco.
18 Dec, 2023
17:21
FinancialContent
Biden To Decide On Psychedelic Therapy Bill
President Joe Biden received the final version of a large-scale defense bill providing ...
05 Dec, 2023
13:00
Yahoo! Finance
CAMBRIDGE, Mass., December 05, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has identified three novel compounds from its EVM301 Series with the potential to offer a first-in-class approach to address difficult-to-treat disorders by promoting neuroplasticity without inducing
29 Nov, 2023
13:00
Yahoo! Finance
CAMBRIDGE, Mass., November 29, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatme
27 Nov, 2023
13:00
Yahoo! Finance
CAMBRIDGE, Mass., November 27, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced a research article describing the development of lead therapeutic candidate, EB-373, a novel psilocin prodrug, will be published on the cover of the Journal of Medicinal Chemistry, a peer-reviewed journal pub
24 Nov, 2023
13:00
Yahoo! Finance
CAMBRIDGE, Mass., November 24, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the presentation of two posters at the Canadian Chemical Engineering Conference (CSChE 2023) which was held October 29th to November 1, 2023.
13 Nov, 2023
CAMBRIDGE, Mass., November 13, 2023--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today provided a corporate update and reported financial results for the third quarter of 2023 ended September 30, 2023.
08 Nov, 2023
31 Oct, 2023
12:00
Yahoo! Finance
CAMBRIDGE, Mass., October 31, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has received a Notice of Allowance (NoA) from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the Company’s new chemical entity (NCE) prodrug of psiloci
20 Oct, 2023
CAMBRIDGE, Mass., October 20, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, announced that Joseph Tucker, Ph.D., Chief Executive Officer, will present at the Centurion One 5th Global Summit being held on October 24-25, 2023 in Nassau, Bahamas.
18 Oct, 2023
12:00
Yahoo! Finance
CAMBRIDGE, Mass., October 18, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced initiation of Good Laboratory Practice (GLP)-toxicology and safety pharmacology studies for lead prodrug candidate EB-373, the company’s next generation psilocin prodrug being developed for the treatment of ps
14 Aug, 2023
24 May, 2023
18 May, 2023
15 May, 2023
03 Apr, 2023
28 Feb, 2023
24 Jan, 2023
24 Oct, 2022
15 Sep, 2022
25 Jul, 2022
11 May, 2022
31 Mar, 2022
11 Feb, 2022
10 Feb, 2022
06 Dec, 2021
18 Nov, 2021
05 Oct, 2021
12:08
Seeking Alpha
17 Sep, 2021
08 Jul, 2021
12:27
Seeking Alpha
31 May, 2021
24 May, 2021
18 May, 2021
15 Apr, 2021
01 Apr, 2021